| Source: TCGA |
| Type: Antiapoptotic |
| Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response. -One way to estimate Nrf2 induction is through the expression of NQO1. NQO1, the most potent inducer: SFN 0.2 μM, quercetin (2.5 μM), curcumin (2.7 μM), Silymarin (3.6 μM), tamoxifen (5.9 μM), genistein (6.2 μM ), beta-carotene (7.2μM), lutein (17 μM), resveratrol (21 μM), indol-3-carbinol (50 μM), chlorophyll (250 μM), alpha-cryptoxanthin (1.8 mM), and zeaxanthin (2.2 mM) 1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects. 2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death. 3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress -In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies. -Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate. Decreased Nrf2 expression: Skine, Liver, Pancreatic. -Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer - "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1. Nrf2 Inhibitors and Activators Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api - potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue. – In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis. – In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity. – This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming. – Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies. – High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types. – While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression. NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS). -Brusatol: most cited natural inhibitors of Nrf2. -Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent. -Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent . -Oridonin: -Wogonin: although its effects might be cell‑ and dose‑specific. - Withaferin A |
| 4780- | Lyco, | Potential inhibitory effect of lycopene on prostate cancer |
| - | Review, | Pca, | NA |
| 4797- | Lyco, | A mechanistic updated overview on lycopene as potential anticancer agent |
| - | Review, | Var, | NA |
| 4795- | Lyco, | Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer |
| - | Review, | BC, | NA |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 1780- | MEL, | Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing |
| - | Review, | Var, | NA |
| 1204- | MET, | Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 5785- | MET, | Metformin improves healthspan and lifespan in mice |
| - | in-vivo, | Nor, | NA |
| 4105- | MF, | Extremely low frequency electromagnetic fields stimulation modulates autoimmunity and immune responses: a possible immuno-modulatory therapeutic effect in neurodegenerative diseases |
| - | Review, | AD, | NA |
| 3457- | MF, | Cellular stress response to extremely low‐frequency electromagnetic fields (ELF‐EMF): An explanation for controversial effects of ELF‐EMF on apoptosis |
| - | Review, | Var, | NA |
| 3462- | MF, | The Effect of a Static Magnetic Field on microRNA in Relation to the Regulation of the Nrf2 Signaling Pathway in a Fibroblast Cell Line That Had Been Treated with Fluoride Ions |
| - | in-vitro, | Nor, | NA |
| 3847- | MSM, | Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement |
| - | Review, | Arthritis, | NA |
| 3848- | MSM, | Modulatory effect of methylsulfonylmethane against BPA/γ-radiation induced neurodegenerative alterations in rats: Influence of TREM-2/DAP-12/Syk pathway |
| - | in-vitro, | AD, | NA |
| - | in-vitro, | AD, | NA |
| 1273- | Myr, | Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4 |
| - | vitro+vivo, | GC, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 1680- | PBG, | Protection against Ultraviolet A-Induced Skin Apoptosis and Carcinogenesis through the Oxidative Stress Reduction Effects of N-(4-bromophenethyl) Caffeamide, a Propolis Derivative |
| - | in-vitro, | Nor, | HS68 |
| 3255- | PBG, | Propolis reversed cigarette smoke-induced emphysema through macrophage alternative activation independent of Nrf2 |
| - | in-vivo, | Nor, | NA |
| 3254- | PBG, | Brazilian green propolis water extract up-regulates the early expression level of HO-1 and accelerates Nrf2 after UVA irradiation |
| - | in-vitro, | Nor, | NA |
| 3251- | PBG, | The Antioxidant and Anti-Inflammatory Effects of Flavonoids from Propolis via Nrf2 and NF-κB Pathways |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Var, | NA | - | in-vitro, | Nor, | H9c2 |
| 3252- | PBG, | Propolis Extract and Its Bioactive Compounds—From Traditional to Modern Extraction Technologies |
| - | Review, | NA, | NA |
| 3253- | PBG, | Brazilian red propolis extract enhances expression of antioxidant enzyme genes in vitro and in vivo |
| - | in-vitro, | Nor, | HEK293 | - | in-vivo, | Nor, | NA |
| 3257- | PBG, | The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review |
| - | Review, | Var, | NA |
| 5014- | PEITC, | Xan, | Combination of xanthohumol and phenethyl isothiocyanate inhibits NF-κB and activates Nrf2 in pancreatic cancer cells |
| - | in-vitro, | PC, | NA |
| 5016- | PEITC, | Phenethyl Isothiocyanate (PEITC) interaction with Keap1 activates the Nrf2 pathway and inhibits lipid accumulation in adipocytes |
| - | in-vitro, | Nor, | NA |
| 4941- | PEITC, | PEITC: A resounding molecule averts metastasis in breast cancer cells in vitro by regulating PKCδ/Aurora A interplay |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5217- | PG, | Role of redox signaling regulation in propyl gallate-induced apoptosis of human leukemia cells |
| - | in-vitro, | AML, | THP1 | - | in-vitro, | AML, | Jurkat | - | in-vitro, | AML, | HL-60 |
| 4220- | PI, | Piperine ameliorated memory impairment and myelin damage in lysolecethin induced hippocampal demyelination |
| - | in-vivo, | AD, | NA | - | in-vivo, | MS, | NA |
| 2946- | PL, | Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent |
| - | Review, | Var, | NA |
| 2948- | PL, | The promising potential of piperlongumine as an emerging therapeutics for cancer |
| - | Review, | Var, | NA |
| 2962- | PL, | Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents |
| - | in-vitro, | Nor, | PC12 |
| 2961- | PL, | Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis |
| - | in-vitro, | ESCC, | KYSE-30 |
| 2960- | PL, | Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents |
| - | Analysis, | Nor, | NA |
| 2955- | PL, | Heme Oxygenase-1 Determines the Differential Response of Breast Cancer and Normal Cells to Piperlongumine |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 2954- | PL, | The metabolites from traditional Chinese medicine targeting ferroptosis for cancer therapy |
| - | Review, | Var, | NA |
| 5163- | PLB, | Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
| 5156- | PTL, | Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells |
| - | in-vitro, | AML, | NA |
| 1985- | PTL, | KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | PrEC | - | in-vivo, | NA, | NA |
| 1987- | PTL, | Rad, | A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | PrEC |
| 3929- | PTS, | New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA |
| 3927- | PTS, | Effects of Pterostilbene on Cardiovascular Health and Disease |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3924- | PTS, | Effect of resveratrol and pterostilbene on aging and longevity |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 5033- | PTS, | Involvement of the Nrf2 Pathway in the Regulation of Pterostilbene-Induced Apoptosis in HeLa Cells via ER Stress |
| - | in-vitro, | Cerv, | HeLa |
| 5032- | PTS, | Pterostilbene Decreases the Antioxidant Defenses of Aggressive Cancer Cells In Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent Mechanism |
| - | in-vivo, | Melanoma, | NA |
| 5034- | PTS, | Pterostilbene in Cancer Therapy |
| - | Review, | Var, | NA |
| 4693- | PTS, | Pterostilbene in the treatment of inflammatory and oncological diseases |
| 4703- | PTS, | RES, | Pterostilbene and resveratrol: Exploring their protective mechanisms against skin photoaging - A scoping review |
| - | NA, | Nor, | NA |
| 39- | QC, | A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells |
| - | Analysis, | NA, | NA |
| 923- | QC, | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
| - | Review, | Var, | NA |
| 4827- | QC, | CUR, | Synthetic Pathways and the Therapeutic Potential of Quercetin and Curcumin |
| - | Review, | Var, | NA |
| 5031- | QC, | Different roles of Nrf2 and NFKB in the antioxidant imbalance produced by esculetin or quercetin on NB4 leukemia cells |
| - | in-vitro, | AML, | APL NB4 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:226 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid